Development of spontaneous neuropathy in NF-κBp50-deficient mice by calcineurin-signal involving impaired NF-κB activation

Tomoko Nakamura-Yanagidaira,1 Yasuko Takahashi,1 Kenji Sano, Toshinori Murata,1 Takuma Hayashi3

1Department of Ophthalmology, Shinshu University Graduate School of Medicine, Nagano, Japan; 2Department of Laboratory Medicine, Shinshu University Hospital; 3Department of Immunology and Infectious Disease, Shinshu University Graduate School of Medicine, Nagano, Japan

Purpose: The transcriptional regulator, nuclear factor-kappa B (NF-κB)/Rel family are involved in neuronal cell death and survival. Previously, we reported that NF-κBp50-deficient (p50-deficient) mice exhibit many features resembling human normal tension glaucoma (NTG). The developmental mechanism of human NTG is not clearly understood, and a radical curative treatment has yet to be established. Our aim is to elucidate the signal cascade which mediates the spontaneous optic neuropathy in p50-deficient mice as a model of NTG.

Methods: To demonstrate the expression and activation of pro-apoptotic factors, which mediate the death of retinal ganglion cells (RGCs) in p50-deficient mice, western blot (WB) and luciferase reporter assays with retinas from p50-deficient and wild type mice, and cultured RGC-5 cells were performed. Furthermore, we tested the neuroprotective effects of chemical reagents (memantine, lomerizine, and tacrolimus) against N-methyl-D-aspartate (NMDA)-susceptible RGC damage according to in vitro experiments with RGC-5 cells. To elucidate the NF-κB-mediated death signaling, the effects of chemical reagents on spontaneous optic neuropathy were examined by histopathological studies.

Results: WB experiments and luciferase reporter assays showed that NF-κB-inducible BCL2-associated X protein (Bax) and a pro-apoptotic factor, activated caspase 3 were expressed in the retina of p50-deficient mice as well as NMDA-treated RGC-5 cells. Further, the constitutively active cleaved forms of calcineurin (CaN), which have been reported to lead to apoptosis, were detected in the retina of p50-deficient mice as well as NMDA-treated RGC-5 cells. Pre-treatment with tacrolimus markedly protected RGC-5 cells from NMDA-induced neurotoxicity, and then both spontaneous RGC death and degenerative changes to the optic nerve in p50-deficient mice were significantly reduced by the chronic administration of tacrolimus. The experiments with cultured RGC-5 cells supported the results of histological examinations with p50-deficient mice, suggesting that CaN activation leads to NF-κB-induced Bax activation and caspase 3 activation, and mediates spontaneous optic neuropathy in p50-deficient mice.

Conclusions: Research findings show that the chronic administration of tacrolimus significantly reduces spontaneous optic neuropathy in p50-deficient mice. We demonstrated a potential CaN signal cascade, which spontaneously induces age-dependent RGC death and degenerative optic nerve changes in p50-deficient mice.

Glucoma, one of the most common causes of visual impairment worldwide, is characterized by the apoptosis of retinal ganglion cells (RGCs) [1]. Although increased intraocular pressure (IOP) has long been considered the primary cause of the cell death, evidence from studies on normal tension glaucoma (NTG) suggests other factors to be involved in the apoptosis of RGCs, which is induced by a potential neurotoxic role for glutamate, genetic background, and autoimmunity [2-4]. Although most anti-glaucomatous reagents are used to lower IOP, in some cases, the patient's condition deteriorates in spite of an IOP within the normal range. Identifying factors, which are quite independent of IOP, would be necessary to understand the pathogenesis of glaucoma and guide efforts toward improved therapeutics.

Nuclear factor-kappa B (NF-κB), which acts as a transcription factor, plays a key role in cell survival or the death signaling pathway, acute central nervous system (CNS) trauma, and chronic neurodegenerative disorders [5,6]. The NF-κB family, which is mainly composed of p50/p65 (RelA) heterodimers, is found in almost all animal cell types, and is involved in cellular responses to stimuli such as stress and cytokines [7]. In unstimulated cells, NF-κB is sequestered to the cytoplasm by a family of inhibitors called IκBs. With the degradation of IκB inhibitor, the NF-κB is then free to enter the nucleus, where it can turn on the expression of specific genes. Recent reports suggest that the binding site of the heterodimer p50-p65 could also be occupied by the homodimer p50-p50, whereupon p50-p50 may function as a repressor to regulate p50-p65's role as a transcription factor which is essential for neuronal response [7]. Impaired regulation of NF-κB has been linked to various diseases, such as cancer, inflammatory disorders, and autoimmune diseases, and has also been implicated in the processes of synaptic plasticity and memory [8]. In the CNS, it has been reported that the activated
NF-κBp65(ReLA) may participate in glutamate-induced neurotoxicity, N-methyl-D-aspartate (NMDA)-induced retinal neuronal cell death, retinal ischemia, and reperfusion injury [9-12]. However, the precise role of NF-κB in cell death within the CNS is controversial.

In many types of neuron, this excitotoxicity appears to be mediated predominantly by signaling pathways, including Ca$^{2+}$ influx through the NMDA receptor, a subtype of the glutamate receptor [13]. For these reasons, it is likely that NMDA antagonists, memantine, dizocilpine (MK-801), and Ca$^{2+}$ channel blockers, such as flunarizine, verapamil, nicardipine, and lomerizine, prevent retinal damage caused by NMDA [14-16]. Calcineurin (CaN) is a Ca$^{2+}$-calmodulin-dependent phosphatase highly expressed in the CNS and retina [17,18]. Activation of CaN leads to apoptosis of cultured neurons [19]. Tacrolimus, a CaN inhibitor, exhibits a neuroprotective effect in a wide range of models of acute apoptotic neuronal death in the CNS, trauma, and stroke [20,21]. In the retina, tacrolimus has been reported to confer neuroprotection on RGCs after optic nerve crush [22]. In addition, an increased IOPs associated with the CaN-mediated mitochondrial apoptotic pathway [23]. Furthermore, tacrolimus has been shown to inhibit glutamate-induced apoptosis in cultured RGCs [24]. Although the neuroprotective effects of these chemical reagents have been examined in transient studies employing glaucoma models, it has yet to be demonstrated whether the chronic administration of chemical reagents to NTG-animal models has protective effects against neuropathy.

Previously, we reported that NF-κBp50-deficient (p50-deficient) mice exhibit a spontaneous loss of RGCs independent of IOP, characteristic excavation of the optic nerve head, and degenerative changes to the optic nerve, with many features resembling human NTG [25]. However, the precise mechanism involved is still unknown. In this study, we tried to identify the death signaling cascade in the initiation of spontaneous optic neuropathy in p50-deficient mice as a model of NTG. The experiments demonstrated neuroprotective effects of several chemical reagents, especially tacrolimus, against NMDA-induced neurotoxicity and spontaneous RGC death in p50-deficient mice. The defect in the p50/p50 homodimer, which functions as a repressor to regulate p50-p65's role, results in optic neuropathy via a CaN signal cascade involving impaired NF-κB activation in p50-deficient mice.

We provide a new insight into the role of NF-κBp50 in the pathophysiology of optic neuropathy, and present experiments involving p50-deficient mice demonstrating the CaN-signaling molecules including NF-κB, suggesting targets for the development of therapeutic reagents. Our research findings may provide new targets for therapeutic intervention in human NTG.

**METHODS**

**Animals:** We purchased mice homozygous for the Nfkb1tmBal target mutation, which have a B6/129-F2 genetic background, from Jackson Laboratories (Bar Harbor, ME), and C57BL/6J mice from CLEA Japan, Inc. (Tokyo, Japan). All wild type, homozygous mice deficient in p50 were littermates of F8 heterozygous mice generated by backcrossing with C57BL/6J mice. All animal-related procedures were performed in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals and the AVRO Statement for the Use of Animals in Ophthalmic and Vision Research. These mice were kept in a specific pathogen-free environment at Shinshu University’s animal facilities, in accordance with institutional guidelines (approval no. 03–28–008). A total of 280 mice (wild type mice; n=90, p50-deficient mice; n=190, at 3 weeks to 10 months of age) were used in this study.

**Labeling and counting in RGCs:** Retrograde labeling was performed as reported [25]. Mice were anesthetized by the intraperitoneal administration of Nembutal (50 mg/kg; Dainippon Sumitomo Pharma, Osaka, Japan). The animals were placed in a stereotaxic apparatus (Narishige, Tokyo, Japan) and the scalp was incised at the midline and retracted laterally to make a burr hole at an appropriate location (2.0 mm posterior to the bregma, 1.2 mm left of the midline) determined according to the mouse brain map. A window was drilled in the scalp, the neurotracer dye Fluoro-Gold (a 4% solution in saline; Fluorochrome, Denver, CO) was applied (1 μl at a rate of 0.5 μl/min in each hemisphere) using a Hamilton syringe, and the skin over the wound was sutured. Five days after the application of Fluoro-Gold, mice were euthanized and, after their eyes were enucleated, the retinas were detached as flattened whole mounts in 4% paraformaldehyde in PBS. Labeled cells from 10 fields of identical size (230×150 μm) were counted under a fluorescence microscope. The counted fields were located at approximately the same distance from the orra serata (500 μm). Fields were counted by 2 blinded observers, and the average number of RGCs per field was calculated for each retina and analyzed by ANOVA with Bonferroni correction.

**Immunohistochemistry (IHC) and immunofluorescence:** The retinas of mice ranging in age from 3 weeks to 10 months were used for research experiments. Mice were euthanized and their eyes were immediately enucleated, the retinas were detached as flattened whole mounts in 4% paraformaldehyde in PBS. Labeled cells from 10 fields of identical size (230×150 μm) were counted under a fluorescence microscope. The counted fields were located at approximately the same distance from the orra serata (500 μm). Fields were counted by 2 blinded observers, and the average number of RGCs per field was calculated for each retina and analyzed by ANOVA with Bonferroni correction.
at 4 °C. Normal rabbit or mouse antiserum was also used as a negative control. After a wash with PBS, the secondary antibody, Alexa Fluor 488-conjugated donkey anti-rabbit IgG (1:200, Invitrogen Corp., Carlsbad, CA), Alexa Fluor 546-conjugated goat anti-rabbit antibody (1:200; Invitrogen), and Alexa fluor 488 conjugated mouse IgG1 antibody (1:200; Invitrogen) were reacted at room temperature for 2 h. Finally, the sections were coverslipped with antifade mounting medium (VECTASHIELD; Vector Laboratory, Inc., Burlingame, CA). Sections were examined under a Leica laser scanning confocal microscope (TCS SP2 AOBS; Leica Microsystems GmbH, Wetzlar, Germany). For in situ TdT-mediated dUTP nick-end labeling (TUNEL) assays, paraffin-embedded retinas were used. The sections were dewaxed and rinsed with PBS. The TUNEL assay was performed using Apop Tag Fluorescein In situ Apoptosis Detection Kit according to the manufacturer’s instructions (MILLIPORE, Billerica, MA). After labeling, the slides were mounted with mounting medium (VECTASHIELD; Vector Laboratories) for fluorescence microscopy with PI nuclear staining.

**Western blot:** The retinas were dissected from mouse eyes derived from wild type and p50-deficient mice, and homogenized in modified RIPA buffer (50 mM Tris [pH7.4]; 1% NP-40; 0.25% Na-deoxycholic acid; 150 mM NaCl; 1 mM EDTA; 1 mM NaF; 1 mM PMSF; 1 mM NaVO3; and aprotinin, leupeptin, pepstatin at 1 μg/ml each). The samples were heated at 95 °C for 10 min and centrifuged at 20,000× g for 20 min, and the supernatants were stored as retinal crude extracts at −30 °C. These extracts (10 μg) were run on a 10% SDS–PAGE, and an immunoblot analysis was performed with a rabbit monoclonal antibody to NF-κBp50 (Epitomics, Inc., Burlingame, CA), rabbit polyclonal antibody to NF-κBp65, rabbit polyclonal antibody to Calcineurin (Exalpha Biologicals Inc., Watertown, MA), rabbit polyclonal antibody to caspase 3 (EMD Bioscience), rabbit polyclonal antibody to p-actin (Santa Cruz technology, Inc., Santa Cruz, CA), and mouse monoclonal antibody to Bax (TREVIGEN) using standard procedures. Immunodetectable proteins were visualized and enhanced using the ECL western blot system (GE Healthcare Bio-Science, Uppsala, Sweden).

**Cytosol and nuclear extracts:** Cultures of retinal ganglion cells (RGC-5, a rat ganglion cell line transfected using the E1A virus), which were provided by Dr. Neeraj Agarwal (UNT Health Science Center, Fort Worth, TX), were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma-Aldrich, St. Louis, MO) containing 10% fetal bovine serum (FBS; Valeant, Costa Mesa, CA), 100 U/ml penicillin (Meiji Seika Ltd., Tokyo, Japan), and 100 μg/ml streptomycin (Meiji Seika Ltd., Tokyo, Japan) in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. The RGC-5 cells were passaged by trypsinization every 3–4 days. Cytosol extracts and nuclear extracts were prepared from 1 × 106 RGC-5 cells. Cells were harvested, centrifuged for 10 min at 130× g, washed in 1 ml of ice-cold PBS, and centrifuged for 15 s at 17,000× g in an Eppendorf Brinkman-5412 centrifuge at 4 °C. Cells were pelleted and washed once in 0.4 ml of buffer A (10mM Heps, pH7.8; 10 mM KCl; 2 mM MgCl2; 1 mM dithiothreitol [DTT]; 0.1 mM EDTA; 0.1 mM phenylmethylsulfonyl fluoride [PMSF]; 5 μg/ml antipain [Sigma, St Louis, MO], and 5 μg/ml leupeptin [Sigma]) and incubated on ice for 15 min. Then, 25 μl of a 10% Nonidet P-40 solution (Sigma) was added, and cells were vigorously mixed for 15 s and centrifuged for 30 s at 17,000× g. Pelleted nuclei were resuspended in 40 μl of buffer C (50 mM Heps, pH 7.8; 50 mM KCl; 300 mM NaCl; 0.1 mM EDTA; 1 mM DTT; and 0.1mM PMSF; 10% [v/v] glycerol), mixed for 20 min, and centrifuged for 5 min at 17,000× g at 4 °C. The supernatant containing the nuclear proteins was harvested, the protein concentration was determined, and the samples was stored at −80 °C.

**Cell transfections and reporter assays:** RGC-5 cells were seeded at 70% confluence in 6-well plates, and a total of 2 μg of luciferase reporter vectors (Bax [full] promoter-Luc and Bax (ΔκB) promoter-Luc), provided by Dr. Chotteau-Lelievre (University of Sciences et Technologies, Cedex, France), was transfected into RGC-5 cells with FuGENE6 Transfection Reagent according to the manufacturer’s recommendations (Roche Diagnostics, Indianapolis, IN). All transfections contained 200 ng of pCMV-LacZ (Roche Diagnostics) as an internal transfection efficiency control. Glutamate (final concentration, 50 μg) was added to the culture medium at 48 h after transfection and the cells were washed for the preparation of whole cell lysates. Cell lysates were prepared 24 h later for the assays of luciferase (Promega Corp., Madison, WI) and p-galactosidase (Galacticlight; Roche Applied Science) activities following the manufacturer’s instructions and using a GloMax®20/20 Luminometer (Promega Corp.). The measured luciferase activity was corrected by using co-transfected pCMV-p-galactosidase activity as an internal control.

**N-methyl-D aspartate (NMDA) injection and morphometric analysis:** The intravitreal injection of NMDA was performed as described previously [25]. A total of 1 μl of 5 or 10 nM solution of NMDA in PBS was injected into the vitreous of one eye. PBS alone was injected into the other eye as a negative control. At 24 h after the injection, the eyes were enucleated and fixed in 4% paraformaldehyde in PBS (Wako, Tokyo, Japan), dehydrated, and embedded in paraffin. Transverse sections were made though the optic disc and orra serata in the ganglion cell layer (GCL) were counted, except the cells infiltrating the GCL. The average number of cells per field was analyzed using the Mann–Whitney U test.

**Chemical reagents:** NMDA receptor antagonists, MK-801 and memantine, were purchased from Sigma-Aldrich Japan.
were examined by EMSA as described [26]. EDTA buffer at 4 °C. NF-κB-binding activities of protein complexes were resolved by electrophoresis on 50 mM KCl, 5 mM Tris-HCl (pH 7.0), 1 mM DTT, 15 mM volume of 10 μl containing 10 mM Hepes-NaOH (pH 7.9), nuclear extracts were incubated for 30 min at 37 °C in a total (5′-ATT CGA TCG GGG CGG GGC GAG C-3′). For EMSA, virus type 1 (HIV-1κB) enhancer or the SP1-binding motif TCC AG-3′) binding motifs of the human immunodeficiency type κB (5′-GAT CTA GGG ACT TTC CGC TGG GGA CTT -3′) promoter. They correspond to wild-type DNAsynthesizer and purified on an OPC cartridge prepared by the phosphoramidate method with a Oligonucleotides and electrophoretic mobility shift assay (EMSA): Double-stranded oligodeoxynucleotides were obtained by the phosphoramidate method with a DNA synthesizer and purified on an OPC cartridge (FASMAC, Inc. Kanagawa, Japan). They correspond to wild-type κB (5′-GAT CTA GGG ACT TTC CGC TGG GGA CTT TCC AG-3′) binding motifs of the human immunodeficiency virus type 1 (HIV-1κB) enhancer or the SP1-binding motif (5′-ATT CGA TCG GGG CGG GGC GAG C-3′). For EMSA, nuclear extracts were incubated for 30 min at 37 °C in a total volume of 10 μl containing 10 mM Hepes-NaOH (pH 7.9), 50 mM KCl, 5 mM Tris-HCl (pH 7.0), 1 mM DTT, 15 mM EDTA, 10% glycerol, 1.0 μg of poly (dI'dC), and 4 ng of wild-type HIV-1κB or SP1 oligonucleotides. The resulting DNA–protein complexes were resolved by electrophoresis on nondenaturating 8% polyacrylamide gels with 0.5× Tris borate-EDTA buffer at 4 °C. NF-κB-binding activities were examined by EMSA as described [26].
nuclear layer (ONL). The RGCs in p50-deficient mice at age 3 weeks, 2 months, 5 months, and 10 months were counted using a retrograde labeling method, and the number at 5 months and 10 months of age (n=each 8~12 mice) had markedly decreased compared with that in wild-type littermates (Figure 1A).

To demonstrate whether the p50-deficiency affected NF-κBp65 activation and RGC survival in the retina, we examined NF-κBp65 expression at 2 months of age. NF-κBp65 was detected in the cytoplasm of RGCs of wild-type mice. Unexpectedly, IHC clearly showed that NF-κBp65 spontaneously localizes in the nucleus of RGCs in p50-deficient mice under normal conditions (Figure 1B); the p50-deficiency in RGCs may result in the induction of NF-κBp65’s neuronal toxicity. Western blot (WB) analysis strongly supports the IHC findings (Figure 1B). Bax and Caspase 3,
which play a key role in the promotion of apoptosis, mediates stress-induced RGC death as well as glutamate-induced apoptosis in cultured neuronal cells [27-29]. Furthermore, Bax is required for the RGC death pathway in DBA/2J mice, which is an IOP-dependent glaucoma model. The WB results showed that Bax expression in the retinas of p50-deficient mice was slightly higher than that in wild-type mice, and further activated forms of caspase 3 were detected in the retinas from p50-deficient mice (Figure 1C). The constitutively active cleaved form of calcineurin (CaN) has been reported to lead to apoptosis by elevating IOP in experimental glaucoma [28]. The WB results showed the presence of the full-length CaN in all retinas examined, and that cleaved CaN occurred only in retinas from p50-deficient mice (Figure 1C).

To determine whether glutamate treatment directly induces Bax expression via NF-κB activation, luciferase reporter assays using cultured RGC-5 cells were performed. Although Bax promoter activity was strongly induced in the experiment using the reporter construct containing the wild-type B-binding site after glutamate-treatment, the activity was not clearly detected using the reporter construct containing the mutated B-binding site (Figure 1D, Appendix 1-Figure 1). These findings show that the p50-deficiency results in a decrease in viable RGCs due to high levels of Bax expression and caspase 3 activation, suggesting that RGCs are spontaneously to undergo apoptosis by a CaN signal cascade in the retina of p50-deficient mice.

The effects of chemical reagents on the susceptibility to NMDA-treatment in p50-deficient mice: NMDA-receptor-mediated excitotoxicity reportedly contributes to glaucomatous neuropathy [12]. Surviving RGCs were counted at 24 h after the intravitreal injection of 10, and 5 nM, NMDA or vehicle (PBS). The treatment with 5 nM or 10 nM NMDA for 24 h markedly induced RGC death in the ganglion cell layer (GCL) in p50-deficient mice, but not in wild-type mice. Morphometric evaluation demonstrated no significant difference in the thickness of the inner plexiform layer (IPL) between the p50-deficient and wild-type mice treated with 5 nM NMDA (Appendix 1-Figure 2A). The IHC experiment clearly showed that after NMDA treatment, NF-κBp65 translocated to the nucleus in the RGCs of the wild-type as well as p50-deficient mice (Appendix 1-Figure 2B).

To determine whether Ca²⁺ signaling molecules mediate NMDA-induced neurotoxicity in p50-deficient mice, we examined the neuroprotective effects of chemical reagents, which act on the Ca²⁺-signaling pathway including CaN activation, on NMDA-induced RGC death. The p50-deficient mice at 2 months of age, showing normal RGC survival, underwent intraperitoneal pretreatments with a NMDA antagonist, MK801 or memantine; calcium blocker, lomerizine; and CaN inhibitor, tacrolimus, daily for 1 week before the injection of 5 nM NMDA (Appendix 1-Figure 3). Histological examination of the retinas at 24 h after the intravitreal injection of NMDA showed protective effects of the chemical reagents against NMDA-induced neurotoxicity (Appendix 1-Figure 4A). Morphometric evaluation indicated marked NMDA-induced neurotoxicity in p50-deficient mice (12.3* 7.2 cells, n=12) in contrast to wild-type mice (17.9* 8.9 cells, n=10). The pre-treatments with chemical reagents markedly protected RGCs from NMDA-induced neurotoxicity (Appendix 1-Figure 4B).

In addition, RGCs were protected from NMDA-induced neurotoxicity on pre-treatment with tacrolimus at the various concentrations indicated in Appendix 1-Figure 4C. The retinal damage was reduced compared with that in mice treated with NMDA alone, even following the systemic injection of a low dose of tacrolimus.

Glutamate-induced RGC apoptosis via calcineurin signal cascade including impaired NF-κB activation: To verify the key role of NF-κBp50 and protective effect of tacrolimus against glutamate/NMDA-induced neurotoxicity, in vitro experiments using cultured RGC-5 cell lines were performed. Glutamate/NMDA-induced neurotoxicity was clearly observed in a dose-dependent manner (Figure 2A). First, p50-overexpression markedly protected RGC-5 cells from glutamate/NMDA-induced neurotoxicity (Figure 2A). A quantitative assessment of the protective effects of tacrolimus is shown in Figure 2A. To demonstrate the biologic effect of p50-overexpression or pre-treatment with tacrolimus on NF-κB expression under glutamate neurotoxicity, the localization of NF-κBp65 and p50 in RGC-5 cells after glutamate-stimulation was examined. WB analysis showed that glutamate markedly induced the expression and nuclear translocation of NF-κB (p65/p50 heterodimer; Figure 2B, lanes 1, 3, 5, and 7). In the case of p50-overexpression, NF-κBp50 was significantly detected in the nucleus without glutamate, and then nuclear NF-κBp50 expression markedly increased after the stimulation (Figure 2B, lanes 2, 4, 6, and 8). Experiments with EMSA revealed that after stimulation with glutamate, NF-κBp50 expression resulted in a large number of p50 homodimer complexes and a slight decrease in p65/p50 heterodimer complexes in comparison with the none transfected-cells (Figure 2C). Although Bax was strongly expressed after glutamate treatment, p50-overexpression reduced the glutamate-induced Bax expression (Figure 2C, lanes 9, 10, 11, and 12). Luciferase-reporter assays supported the WB results, suggesting that p50-overexpression significantly prevented glutamate-induced Bax expression (Figure 2C). It is possible that the binding site of the heterodimer p50-p65 could also be occupied by the homodimer p50-p50, whereupon p50-p50 may function as a repressor to regulate p50-p65’s role as a transcription factor essential for neuronal response [30,31] (Appendix 1-Figure 6).
Figure 2. Systematic neuroprotection by systemic application of tacrolimus or p50 expression in cultured RGC-5 cells. A: Quantitative assessment of the protective effects of p50 expression and tacrolimus against NMDA- or glutamate-induced neurotoxicity. Cell viability was markedly decreased by the application of glutamate or tacrolimus. Neuroprotective effects of p50 expression or tacrolimus were observed. B: western blot analysis indicates the effects of p50 overexpression or tacrolimus (Tac.) pre-treatment on NF-κBp65 and p50 expression in RGC-5 cells after glutamate treatment; nucleus (Nuc.) and cytosol (Cyt.). C: Electrophoretic mobility shift assay (EMSA) demonstrates the effects of p50 overexpression or tacrolimus pre-treatment on NF-κB (p65/p50) activation before and after glutamate treatment. Nuclear extracts were incubated with a double-stranded oligonucleotide spanning the two B binding sites within the murine bax promoter (B sites). The arrows indicate the position of the protein-DNA complexes. Each lane contains the B sites probe (P) without (lane 1) or with the nuclear extracts prepared from control cells (C) RGC-5 cells (lane 2 and 5), RGC-5 cells transfected with the p50 expression vector (lane 3 and lane 6), and RGC-5 cells pre-treated with tacrolimus (Tac.; lane 4 and lane 7). Western blot analysis using whole cell extracts also indicates Bax levels under the culture conditions with p50 overexpression (left panel, lane 10, 12) or tacrolimus pre-treatment (right panel, lane 10, 12). D: The luciferase reporter vectors containing the wild-type or mutated B fragments of the PMBaxSacI bax promoter (−386 to −1) or the corresponding empty luciferase reporter vector (shown in Appendix 1-Figure 1) were transiently co-transfected with or without the NF-κBp50 expression vector into RGC-5 cells. RGC-5 cells were pre-treated with tacrolimus for 24 h at 48 h after transfections with the luciferase reporter vectors. Following pre-treatment with tacrolimus, RGC-5 cells were stimulated by glutamate for 24 h, and then luciferase activities were measured. Values were normalized to those obtained with the co-transfected pSV-β-galactosidase expression vector. Each assay was performed at least three times in triplicate. Data are presented as the mean for three independent experiments (±S.D.). E: western blot analysis indicates the effects of p50 overexpression or tacrolimus (Tac.) pre-treatment on caspase 3 and calcineurin (CaN) activations in RGC-5 cells after glutamate treatment. Although the glutamate treatment activated caspase 3 and cleaved CaN, p50 overexpression resulted in a decrease in both active caspase 3 and cleaved CaN expression in RGC-5 cells after glutamate treatment. The pre-treatment with tacrolimus completely inhibited the glutamate-induced activation of calcineurin, and slightly decreased the level of activated caspase 3.
Figure 3. Neuroprotection by various chemical reagents in p50-deficient mice. A: Bar graph shows RGC survival at 8 months old p50-deficient (KO) and wild-type (WT) mice. Values represent the mean *±SD (n=each 5 11). RGC numbers of KO mice were significantly decreased (**p<0.0001). However, the chronic administration of lomerizine or tacrolimus to KO mice for 6 months resulted in an increase in surviving RGC numbers (**p<0.0001). The chronic administration of memantine to KO mice for 6 months mildly protects RGCs from neurotoxicity (p=0.015). The number of surviving RGCs was counted using retrograde labeling methods. Data was analyzed by Bonferroni correction. B: Photographs show a high-power view of retrograde-labeled RGCs of flat mounts derived from KO and WT mice at 8 months of age. Scale bar=100 μm. C: TUNEL staining using the Apop Tag fluorescein labeled kit (Millipore) plus tissue sections from 2-month-old wild type (WT) mice and p50-deficient (KO) mice, and 10-month-old wild type (WT) mice and KO mice with and without chronic administration of tacrolimus. TUNEL staining was observed in the GCL of 10-month-old KO mice, but not age-matched KO mice treated with tacrolimus (Tac.) or WT mice.
Glutamate did not markedly induce NF-κBp50 expression in the cytosol or nucleus on pre-treatment with tacrolimus (Figure 2B, lanes 2, 4, 6, and 8). The pre-treatment with tacrolimus reduced the glutamate-induced translocation of NF-κB (p65/p50) from the cytosol to nucleus in RGC-5 cells (Figure 2B, lanes 7 and 8); the results obtained by EMSA strongly supported the WB results (Figure 2C). Glutamate-induced Bax expression was weakly observed in the cultures pre-treated with tacrolimus. Luciferase-reporter assays using Bax (full) promoter-Luc and Bax (ΔκB) promoter-Luc (Appendix 1-Figure 1) supported the WB results, suggesting the prevention of glutamate-induced Bax expression by pre-treatment with tacrolimus (Figure 2D). Although activated caspase 3 was clearly detected in RGC-5 cells after glutamate treatment, the overexpression of p50 or pre-treatment with tacrolimus resulted in a reduction in activated caspase 3 levels in glutamate-stimulated RGC-5 cells (Figure 3E). Cleaved CaN was observed in RGC-5 cells overexpressing p50 and control RGC-5 cells after glutamate treatment, and pre-treatment with tacrolimus inhibited CaN activation in the glutamate-stimulated RGC-5 cells (Figure 3E). As a result, the neuroprotective effect of pre-treatment with tacrolimus on glutamate-induced neurotoxicity is attributed to the prevention of CaN-induced NF-κB expression.

The neuroprotective effect of chronic administration of chemical reagents: In the present study, we investigated the age-related survival of RGCs in p50-deficient mice, and whether the chronic administration of tacrolimus prevents the development of spontaneous optic neuropathy. We examined the neuroprotective effect of the chronic administration of chemical reagents on the development of spontaneous optic neuropathy. The intraperitoneal application of tacrolimus, and additional reagents, memantine and lomerizine, which reportedly have neuroprotective effects, daily for 8 months to p50-deficient mice was performed, and then the surviving RGCs were counted using retrograde labeling (Appendix 1-Figure 5). The p50-deficient mice treated with the chronic administration exhibited a significant age-related decline in RGC numbers for 10 months compared with wild-type mice (Figure 3A). The p50-deficient mice treated with chemical reagents showed the following RGC counts: memantine: 69.1* 23.8 (n=9), lomerizine: 74.6* 19.4 (n=5), tacrolimus: 75.4* 18.6 (n=5); Figure 3A). Statistical analysis of the cell counts of dye-filled RGCs in flat-mounted retinas revealed significant differences between the treatments with and without chemical reagents, tacrolimus, memantine, and lomerizine (Figure 3B). The appearance of TUNEL-positive RGCs of p50-deficient mice was markedly decreased by the chronic administration of tacrolimus (Figure 3C). These in vivo experiments provided strong evidence supporting our hypothesis regarding the protective effects of the chronic administration of chemical reagents, especially tacrolimus, against age-dependent spontaneous RGC death.

The clear excavation of the optic nerve head is observed at 10 months of age in p50-deficient mice [25]. Importantly, in the case of chemical reagent-treated mice, histological abnormalities of the optic nerve head were not detected in any mice examined (memantine: n=9, lomerizine: n=5, tacrolimus: n=5; Figure 4A). As shown in the azan staining experiments, although an increase in collagenous fibers (blue staining) caused by axonal loss was clearly detected in the optic nerve sections of p50-deficient mice, the chronic administration of tacrolimus markedly suppressed collagenous fibers (Figure 4B, upper panel). Electron microscopic analysis of a cross-sectioned optic nerve revealed that the area of each axon at 8 months of age expanded considerably more in p50-deficient mice than age-matched wild-type mice, in association with a decrease in the number of axons (Figure 4B, lower panel). However, on the chronic administration of tacrolimus, neither a decrease in the number of axons nor an increase in the area of connective tissue surrounding the axons was seen (Figure 4B, lower panel). Although the number of axons significantly decreased in p50-deficient mice compared to age-matched wild type mice, it did not decrease in the mice treated with tacrolimus (Figure 4C, n=each 5). The chronic administration of chemical reagents, especially tacrolimus, effectively protected not only RGCs but also the optic nerve from spontaneous neuropathy. The amount of Bax in RGCs of p50-deficient mice was markedly decreased by the chronic administration of tacrolimus (Figure 4D).

**DISCUSSION**

NTG shows chronic optic neuropathy and results in a loss of the visual field independently of IOP. Several population studies have suggested that NTG represents 20%–90% of all primary open angle glaucoma, with percentages seeming to vary according to race [32]. Factors, quite independent of IOP, may contribute to disease progression and recent studies have shown that glaucoma is affected by multiple genetic and environmental factors [33,34]. It should be noted that many NTG patients continue to suffer visual field loss in spite of a sufficient reduction in IOP. It is therefore important to understand the pathogenesis of NTG and establish methods of treatment.

Studies of postmortem brain tissues from patients with neurodegenerative disorders such as Alzheimer or Parkinson disease revealed increased NF-κB activity closely associated with the neurodegenerative process. NF-κB reportedly regulates apoptosis in response to stress in the nervous system, in addition to regulating apoptosis in a large variety of cells and tissues. It is difficult to perform analyses using human materials, and so animal studies complement human studies and provide important insights into human NTG. Although glutamate transporter-deficient mice also exhibit spontaneous RGC death and optic nerve degeneration without an increase in IOP, the mice don't show symptoms of chronic ailments
Figure 4. The histopathological changes and decrease in Bax expression in p50-deficient (O) mice with chronic administration of tacrolimus:

A: Light micrographs of cross sections derived from the un-treated wild type (WT), and p50-deficient (KO) mice at 10 month of ages, and the age-matched KO mice treated by chronic administration of tacrolimus, lomerizine or memantine. Although the histopathological results show obvious excavation of the optic nerve head and RGC loss in the un-treated KO mice, no cupping is observed in the KO mice treated by chronic administration of tacrolimus, lomerizine or memantine. Serious losses in surviving RGCs are not detected in the KO mice treated with tacrolimus. Original magnification; (upper panels, low magnification 5×; lower panels, high magnification 20×).

B: Azan staining; although the increase in collagenous fibers (blue color staining) caused by the axonal loss was clearly detected in optic nerve sections of KO mice, the chronic administration of tacrolimus prevented the increase (upper panel: original magnification; 40×). Electron microscopic examinations were performed for detection of morphological abnormalities of cross-sectioned optic nerve axons (lower panel). The KO mice exhibit an expanding area of each axon as well as decreasing number of axons in comparison with age-matched WT mice (lower panel). The area of connective tissue was significantly increased in KO mice (lower panel). However, these changes were not observed in the KO mice with the chronic administration of tacrolimus (lower panel). Scale bar=10 μm. C: The numbers of axons were counted from 10 fields of identical size (18 μm×18 μm). The Bar graph shows a significant decrease at 10 months of age in KO mice compared to parental mice (WT) and the KO mice treated with tacrolimus (Tac.). Data were analyzed by the Mann–Whitney U-test (**p<0.0001, *p<0.001).

D: Immunohistochemical staining with a-Bax antibody (clone 6A7) or normal mouse serum plus tissue sections from 9-month-old wild type mice (WT) and p50-deficient (KO) mice with and without chronic administration of tacrolimus. Bax expression was observed in the GCL of KO mice, but not age-matched KO mice treated with tacrolimus (Tac.) or WT mice. GCL=ganglion cell layer, IPL=inner plexiform layer. Green; Bax, Red; PI. Original magnification; 100×.
such as in human NTG [35]. On the other hand, p50-deficient mice revealed chronic spontaneous optic neuropathy with many features resembling human NTG [25]. Because NF-κB plays such a crucial role in optic neuropathy as well as the nervous system [36-39], it is important to identify the signaling pathways leading to its activation in neurons. In our study, the constitutively active cleaved form of CaN, which has been reported to lead to apoptosis, was detected in the retina of p50-deficient mice, and then the IHC experiments showed that NF-κBp65 spontaneously translocates into the nucleolus of RGCs of p50-deficient mice (Figure 1B). Bax expression in the retina was higher in p50-deficient mice than wild type mice, and activated caspase 3 was observed in p50-deficient mice (Figure 1C). Examinations using the RGC-5 cell line also demonstrated that NF-κBp50 expression contributed greatly to the prevention of NMDA/glutamate-induced neurotoxicity and is required to protect the RGCs and optic nerve from spontaneous optic neuropathy (Figure 3). In short, p50 itself can form p50/p50 homodimers, which generally function as transcriptional repressors to regulate p50/p65's role as a transcription factor [27,40] (Appendix 1-Figure 6). Our studies suggested that the p50 deficiency leads to CaN-induced NF-κBp65 activation resulting in spontaneous RGC death based on recent research findings.

As the stimulation of glutamate receptors results in membrane depolarization which opens Ca$^{2+}$ channels, leading to a rise in the intracellular Ca$^{2+}$ concentration, Ca$^{2+}$ could play an important role in NF-κB activity during optic neuropathy. NF-κB's activation by various stimuli has already been shown to require Ca$^{2+}$ for proper signal transduction [41,42]. However, the exact process involved in transducing the Ca$^{2+}$ signal in optic neuropathy remains to be elucidated. To address this, we analyzed the neuroprotective effects of a Ca$^{2+}$ blocker on RGCs in p50-deficient mice. A protective effect of the chemical reagents, which act on the Ca$^{2+}$-signaling pathway, against spontaneous optic nerve neuropathy was clearly demonstrated based on the chronic administration of reagents to p50-deficient mice as well as transient experiments (Figure 2A, Figure 4A).

CaN, a ubiquitously expressed Ca$^{2+}$/calmodulin-dependent protein kinase II (CaMKII) -dependent protein phosphatase that is a critical component of several Ca$^{2+}$-dependent signaling pathways, controls transcriptional regulation, cell cycle progression, and cell survival. A recent report demonstrated a marked decrease in the level of NF-κB constitutive activity when CaN was specifically inhibited, at both nuclear translocation and transactivation levels, suggesting the central importance of CaN in NF-κB activity in neurons [43]. Cleaved CaN was detected in the retina of p50-deficient mice (Figure 1C), and then the protective effect of tacrolimus against optic neuropathy was elucidated by transient experiments as well as chronic administration to

---

**Figure 5.** Putative biologic function of NF-κB in spontaneous optic neuropathy in NF-κBp50- deficient mouse. A calcineurin (CaN) signal cascade involving impaired NF-κB activation induces spontaneous RGC death.
p50-deficient mice (Figure 2 and Figure 3). Even though RGC-5 cells were stimulated by glutamate, the pre-treatment with tacrolimus reduced activated caspase 3 and Bax expression in RGC-5 cells. The amount of Bax in RGCs and TUNEL-positive RGCs of p50-deficient mice was markedly decreased by the chronic administration of tacrolimus (Figure 3C and Figure 4D). These research findings suggest that a CaN signal cascade involving impaired NF-B activation induces spontaneous RGC death (Figure 5).

Several studies have shown the potential role of the immune system, i.e., autoantibodies against ocular antigens, in the pathogenesis of glaucoma [2]. The p50-deficient mice exhibited multiple immune response defects [7]. Our previous data demonstrated the possible production of autoantibodies in the retinas of p50-deficient mice [25]. Tacrolimus is an immunosuppressive reagent whose main use is after allogenic organ transplant to reduce the activity of the patient’s immune system, and so lower the risk of organ rejection. Therefore, another possibility is that tacrolimus inhibits the immune system, especially autoimmunity. To clarify the mechanism by which tacrolimus promotes RGC survival, further studies must be performed.

One important issue that remains to be resolved in neuronal physiology is how a signal that is released by neurotransmitters binding to their receptors at the synapse, and is transduced into the nucleus to activate gene transcription. Despite the importance of NF-kB to neuronal function and survival, little is known about the signaling pathways leading to its activation. In this study, we demonstrated that p50 expression is required for optic nerve cell survival, suggesting a connection between the loss of p50 expression and optic neuropathy. The mechanism whereby CaN-dependent pathways activate NF-kB is still unknown; we have chosen to utilize p50-deficient mice as well as RGC-5 cells to investigate the mechanisms by which the CaN signal cascade stimulates NF-kB-mediated neuronal cell death. The factors that act on the CaN-dependent pathway might become targets in the clinical treatment of NTG. Clinical studies have shown that there is a correlation between NTG and migraine with aura (MA); significant evidence of alinkage was found between MA phenotype and the marker D4S1647 on 4q24, where the NF-kBp50-coding gene is located [44]. Unfortunately, scientific evidence which directly shows a correlation between defective p50 expression and NTG has yet to be obtained.

In conclusion, tacrolimus protects RGCs from chronic spontaneous optic neuropathy, and then a CaN signal cascade including NF-kB activation induced chronic spontaneous optic neuropathy. Our results provide a new framework for understanding how cross-talk integrates a variety of signals in a physiologic context for the initiation of chronic optic neuropathy. These findings provide strong additional information regarding therapeutic targets for NTG.

ACKNOWLEDGMENTS
We are grateful to Dr. Amer A. Beg (University of South Florida) for helpful discussions about the research findings. This study was supported in part by grants from the Ministry of Education, Culture, Science and Technology, and the Japan Foundation for Prevention of Blindness.

REFERENCES
1. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999; 18:39-57. [PMID: 9920498]
2. Tezel G, Wax MB. Glaucoma. Chem Immunol Allergy 2007; 92:221-7. [PMID: 17264498]
3. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996; 37:1618-24. [PMID: 8675405]
4. Votruba M. Molecular genetic basis of primary inherited optic neuropathies. Eye (Lond) 2004; 18:1126-32. [PMID: 15534598]
5. Baeuerle PA, Baltimore D. IkappaB: aspecificinhibitor of theNF-kappa B transcription factor. Science 1988; 242:540-6. [PMID: 3140380]
6. Mattson MP, Meffert MK. Roles of NF-kappa B in nerve cell survival, plasticity, and disease. Cell Death Differ 2006; 13:852-60. [PMID: 16397579]
7. Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell 1995; 80:321-30. [PMID: 7834752]
8. Hoffmann A, Lung TH, Baltimore D. Genetic analysis of NF-kappa B/Rel transcription factors defines functional specificities. EMBO J 2003; 22:5530-9. [PMID: 14532125]
9. Fan W, Cooper NG. Glutamate-induced NFkappaB activation in the retina. Invest Ophthalmol Vis Sci 2009; 50:917-25. [PMID: 18836176]
10. Grilli M, Pizzi M, Memo M, Spano P. Neuroprotection byaspirin and sodium salicylate through blockade of NF-kappab activation. Science 1996; 274:1383-5. [PMID: 8910280]
11. Nakai M, Qin ZH, Chen JF, Wang Y, Chase TN. Kainic acid-induced apoptosis in rat striatum is associated with nuclear factor-kappa B activation. J Neurochem 2000; 74:647-58. [PMID: 10646516]
12. Chen YG, Zhang C, Chiang SK, Wu T, Tso MO. Increased nuclear factor- kappa B p65 immunoreactivity following retinal ischemia and reperfusion injury in mice. J Neurosci Res 2003; 72:125-31. [PMID: 12645086]
13. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuroon 1988; 1:623-34. [PMID: 2908446]
14. Lam TT, Abler AS, Kwong JM, Tso MO. N-Methyl-D-Aspartate (NMDA)–induced apoptosis in rat retina. Invest Ophthalmol Vis Sci 1999; 40:2391-7. [PMID: 10476807]
15. Lipton SA. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage. Surv Ophthalmol 2003; 48:S38-46. [PMID: 12852433]
16. Torigo N, Akaike A, Yasuyoshi H, Zhang S, Kashi S, Honda Y, Shimazawa M, Hara N. Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/
reperfusion damage in rat retina. Exp Eye Res 2000; 70:475-84. [PMID: 10865996]

17. Seitz DP, Pasha MK, Singh B, Chu A, Sharma RK. Localization and characterization of calcineurin in bovine eye. Invest Ophthalmol Vis Sci 2002; 43:15-21. [PMID: 11773007]

18. Nakazawa A, Usuda N, Matsu T, Hanai T, Matsushita S, Arai H, Sasaki H, Higuchi SJ. Localization of calcineurin in the mature and developing retina. J Histochem Cytochem 2001; 49:187-95. [PMID: 11556687]

19. Wu HY, Tomizawa K, Oda Y, Wei F, Lu YF, Matsushita M, Li ST, Moriwaki A, Matsu H. Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 2004; 279:4929-40. [PMID: 14627704]

20. Sharkey J, Butcher SP. Immunophilins mediate the neuroprotective effects of FK506 in focal cerebral ischaemia. Nature 1994; 371:336-9. [PMID: 75522303]

21. Saxena K, Patro N, Patro I. FK506 protects following peripheral nerve injury via immunosuppression. Cell Mol Neurobiol 2007; 27:1049-57. [PMID: 18080746]

22. Freeman EE, Grosskreutz CL. The effects of FK506 on retinal ganglion cells after optic nerve crush. Invest Ophthalmol Vis Sci 2000; 41:1111-5. [PMID: 10752948]

23. Huang W, Fileta JB, Dobberfuhl A, Filippopolous T, Guo Y, Kwon G, Grosskreutz CL. Calcineurin cleavage is triggered by elevated intracocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc Natl Acad Sci USA 2005; 102:12242-7. [PMID: 16103353]

24. Kikuchi K, Onda Y, Wei F, Lu YF, Matsushita M, Li ST, Moriwaki A, Matsu H. Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 2004; 279:4929-40. [PMID: 14627704]

25. Takahashi Y, Katai N, Murata T, Taniguchi SI, Hayashi T. Essential role of human leukocyte antigen-encoded subunits in NF-kappaB activation and characterization of calcineurin in bovine eye. Invest Ophthalmol Vis Sci 2002; 43:15-21. [PMID: 11773007]

26. Hayashi T, Faustman D. Essential role of human leukocyte antigen-encoded subunits in NF-kappaB activation and prevention of tumor necrosis factor-alpha-induced apoptosis. J Biol Chem 2000; 275:5238-47. [PMID: 10671572]

27. Iriyama T, Kamei Y, Kozuma S, Taketani Y. Bax-inhibiting peptide protects glutamate-induced cerebellar granule cell death by blocking Bax translocation. Neurosci Lett 2009; 451:11-5. [PMID: 19110033]

28. Huang W, Fileta JB, Dobberfuhl A, Filippopolous T, Guo Y, Kwon G, Grosskreutz CL. Calcineurin cleavage is triggered by elevated intracocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc Natl Acad Sci USA 2005; 102:12242-7. [PMID: 16103353]

29. Youle RJ, Strasser A. The BCL-2-protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9:47-59. [PMID: 18097445]

30. Guan H, Hou S, Ricciardi RP. DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase A catalytic subunit. J Biol Chem 2005; 280:9957-62. [PMID: 15642694]

31. Perkins ND, Schmid RM, Duckett CS, Leung K, Rice NR, Nabel GJ. Distinct combinations of NF-kappaB subunits determine the specificity of transcriptional activation. Proc Natl Acad Sci USA 1992; 89:1529-33. [PMID: 1542644]

32. Bonomi L, Marchini G, Marraff M, Bernardi P, De Franco I, Perfetti S, Varotto A, Tema V. Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study. Ophthalmology 1998; 105:209-15. [PMID: 9479277]

33. Osborne NN, Lascorats G, Bron AJ, Chidlow G, Wood JP. AHypothesis to suggest that light is a risk factor in glaucoma and the mitochondrial optic neuropathies. Br J Ophthalmol 2006; 90:237-41. [PMID: 16424541]

34. Wiggs JL. Genetic etiologies of glaucoma. Arch Ophthalmol 2007; 125:30-7. [PMID: 17210849]

35. Harada T, Harada C, Nakamura K, Quah HM, Okumura A, Namekata K, Saeki T, Aihara M, Yoshida H, Mitani A, Tanaka K. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 2007; 117:1763-70. [PMID: 17607354]

36. Hunot S, Bragg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Fauchex BA, Agid Y, Hirsch EC. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997; 94:7531-6. [PMID: 9207126]

37. Kalt Schmidt B, Uher M, Volk B, Baeuerle PA, Kalt Schmidt C. Transcription factor NF-kappaBis activated in primary human neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997; 94:2624-7. [PMID: 9122249]

38. Lipton SA. Janus faces of NF-kappa B: neurodestruction versus neuroprotection. Nat Med 1997; 3:20-2. [PMID: 8986730]

39. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20:252-8. [PMID: 9185306]

40. Har A, Morita T, Sukamoto T, Cutrer FM. Lomerizine (KB-2796), a new antimigraine drug. CNS Drug Reviews 1995 1:204-26.

41. Jefferson KK, Smith JrMF, Bobak DA. Roles of intracellular calcium and NF-kappa B in the Clostridium difficile toxin A-induced up-regulation and secretion of IL-8 from human monocyes. J Immunol 1999; 163:5183-91. [PMID: 10553038]

42. Pahl HL, Baeuerle PA. Activation of NF-kappa B by ER stress requires both Ca2+ and reactive oxygen intermediates as messengers. FEBS Lett 1996; 392:129-36. [PMID: 8772190]

43. Harada T, Harada C, Nakamura K, Quah HM, Okumura A, Namekata K, Saeki T, Aihara M, Yoshida H, Mitani A, Tanaka K. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 2007; 117:1763-70. [PMID: 17607354]

44. Harada T, Harada C, Nakamura K, Quah HM, Okumura A, Namekata K, Saeki T, Aihara M, Yoshida H, Mitani A, Tanaka K. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 2007; 117:1763-70. [PMID: 17607354]

45. Harada T, Harada C, Nakamura K, Quah HM, Okumura A, Namekata K, Saeki T, Aihara M, Yoshida H, Mitani A, Tanaka K. The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma. J Clin Invest 2007; 117:1763-70. [PMID: 17607354]

46. Hunot S, Bragg B, Ricard D, Michel PP, Muriel MP, Ruberg M, Fauchex BA, Agid Y, Hirsch EC. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc Natl Acad Sci USA 1997; 94:7531-6. [PMID: 9207126]

47. Kalt Schmidt B, Uher M, Volk B, Baeuerle PA, Kalt Schmidt C. Transcription factor NF-kappaBis activated in primaryhuman neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 1997; 94:2624-7. [PMID: 9122249]

48. Lipton SA. Janus faces of NF-kappa B: neurodestruction versus neuroprotection. Nat Med 1997; 3:20-2. [PMID: 8986730]

49. O'Neill LA, Kaltschmidt C. NF-kappa B: a crucial transcription factor for glial and neuronal cell function. Trends Neurosci 1997; 20:252-8. [PMID: 9185306]

50. Har A, Morita T, Sukamoto T, Cutrer FM. Lomerizine (KB-2796), a new antimigraine drug. CNS Drug Reviews 1995 1:204-26.
Appendix 1. Supplemental Information.

To access the data, click or select the words “Appendix 1.” This will initiate the download of a compressed (pdf) archive that contains the file.